BioSpace News Archive

Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced financial results for the quarter ended March 31, 2021.

Acerus Pharmaceuticals Corporation reported its financial results for the three-month period ended March 31, 2021.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, to be held virtually June 4 – 8, 2021 and the European Hematology Association (EHA) annual congress, to be held virtually June 9 – 17, 2021.

MindMed, a leading psychedelic-inspired medicine company has appointed Peter Mack PhD as Vice President of Pharmaceutical Development.

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the first quarter ended March 31, 2021 and provided key business updates.

Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2021 operating results on Monday, May 17, 2021 before the open of the U.S. financial markets.

Brooklyn ImmunoTherapeutics, Inc., a biopharmaceutical company exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, announced the appointment of Christopher Rohde, Ph.D. to the Company’s Scientific Advisory Board, effective May 13, 2021.

- Apitegromab shows transformative potential in spinal muscular atrophy (SMA) with 74% of patients with non-ambulatory Type 2 and 3 SMA in the TOPAZ Phase 2 trial attaining a clinical improvement in HFMSE at 12 months - Mean increase from baseline in HFMSE of 6.2 points (across both evaluated doses) observed in younger non-ambulatory patients; up to 20-point increases in HFMSE observed with 35% of patients demonstrating a >10-point increase

Pharmaceutical trials for Alzheimer’s have failed repeatedly, but a new study, using a fundamentally different approach, has provided the first success: using precision medicine to identify and target the drivers of Alzheimer’s or pre-Alzheimer’s in each patient,

Dynatronics Corporation, a leading manufacturer of athletic training, physical therapy, and rehabilitation products, announced financial results for its third quarter of fiscal year 2021 for the period ended March 31, 2021.